Published in Environ Health Perspect on October 01, 1999
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control. J Biomed Biotechnol (2004) 1.05
Aging and the environment: a research framework. Environ Health Perspect (2005) 1.03
Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation (2002) 1.00
Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol (2011) 0.95
Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease. Prostaglandins Leukot Essent Fatty Acids (2011) 0.85
The Functions of PPARs in Aging and Longevity. PPAR Res (2007) 0.78
Activation of Peroxisome Proliferator-Activated Receptor Alpha Improves Aged and UV-Irradiated Skin by Catalase Induction. PLoS One (2016) 0.75
Phthalate-Induced Liver Protection against Deleterious Effects of the Th1 Response: A Potentially Serious Health Hazard. PPAR Res (2007) 0.75
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 11.92
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
Biogenesis of peroxisomes. Annu Rev Cell Biol (1985) 8.12
Mechanisms and functions of cell death. Annu Rev Cell Biol (1991) 7.76
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A (1997) 7.07
Correlated morphometric and biochemical studies on the liver cell. I. Morphometric model, stereologic methods, and normal morphometric data for rat liver. J Cell Biol (1969) 6.74
REGENERATION OF MAMMALIAN LIVER. Int Rev Cytol (1963) 5.34
The PPARalpha-leukotriene B4 pathway to inflammation control. Nature (1996) 5.14
Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A (1992) 4.38
Metabolic pathways in peroxisomes and glyoxysomes. Annu Rev Biochem (1981) 4.06
The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta (1984) 3.58
Biochemistry of peroxisomes. Annu Rev Biochem (1992) 3.51
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A (1997) 3.22
Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science (1973) 2.91
Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J (1995) 2.64
Correlated morphometric and biochemical studies on the liver cell. II. Effects of phenobarbital on rat hepatocytes. J Cell Biol (1969) 2.41
Peroxisomal disorders: a newly recognised group of genetic diseases. Eur J Pediatr (1986) 2.05
cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry (1993) 2.03
Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A (1984) 1.75
Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. J Pediatr (1995) 1.73
Induction of peroxisomal beta-oxidation in rat liver by high-fat diets. Biochem J (1980) 1.70
Cell aging in vivo and in vitro. Mech Ageing Dev (1997) 1.70
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem (1999) 1.65
Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr (1995) 1.63
Liver regeneration 3: Regulation of signal transduction during liver regeneration. FASEB J (1996) 1.50
Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci (1995) 1.50
Unified theory on the basic mechanism of normal mitotic control and oncogenesis. J Theor Biol (1971) 1.48
The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J Biol Chem (1994) 1.41
Hepatic changes produced by a single dose of endotoxin in the mouse. Electron microscopy. Am J Pathol (1968) 1.26
Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol (1994) 1.24
Protein synthesis and degradation during aging and senescence. Biol Rev Camb Philos Soc (1983) 1.23
EXPERIMENTAL STUDIES OF THE TOXICITY OF ATROMID WITH PARTICULAR REFERENCE TO FINE STRUCTURAL CHANGES IN THE LIVERS OF RODENTS. J Atheroscler Res (1964) 1.22
Cellular and molecular mechanisms of aging. Physiol Rev (1993) 1.22
Biochemistry of peroxisomes in health and disease. Mol Cell Biochem (1997) 1.16
Changes in peroxisomal fatty acid oxidation in the diabetic rat liver. J Biochem (1981) 1.16
Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis (1998) 1.13
A morphometric study of age-dependent changes in mitochondrial population of mouse liver and heart. J Gerontol (1976) 1.09
Membrane phospholipid metabolism and signal transduction for protein phosphorylation. Adv Cyclic Nucleotide Protein Phosphorylation Res (1984) 1.08
Activities of antioxidant enzymes in various tissues of male Fischer 344 rats are altered by food restriction. J Nutr (1995) 1.05
Effect of diabetes and starvation on the activity of rat liver epoxide hydrolases, glutathione S-transferases and peroxisomal beta-oxidation. Biochem Pharmacol (1989) 1.03
Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol (1993) 1.00
Microbody formation in regenerating rat liver. J Histochem Cytochem (1970) 0.99
Aging and the liver. Prog Liver Dis (1986) 0.96
Aging and regulation of apoptosis. Curr Top Cell Regul (1997) 0.93
RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol (1998) 0.90
Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis (1982) 0.90
Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol Appl Pharmacol (1986) 0.89
Modification of mitochondrial respiration by aging and dietary restriction. Mech Ageing Dev (1980) 0.89
On the role of the peroxisome in ontogeny, ageing and degenerative disease. Mech Ageing Dev (1995) 0.88
Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease. Crit Rev Toxicol (1998) 0.88
Changes in the expression of superoxide dismutase and catalase as a function of age and dietary restriction. Biochem Biophys Res Commun (1989) 0.88
Catalase turnover in rat liver and kidney as a function of age. Exp Gerontol (1973) 0.87
Peroxisomal beta-oxidation activity and catalase activity during development and aging in mouse liver. Biochimie (1995) 0.87
Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J Cell Biol (1994) 0.86
Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver. Carcinogenesis (1991) 0.86
Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol (1989) 0.85
The role of membrane structure and function in cellular aging: a review. Mech Ageing Dev (1979) 0.85
Age changes in signal transduction and gene expression. Mech Ageing Dev (1997) 0.84
The effect of age on mitochondrial ultrastructure. Gerontologia (1975) 0.84
Species differences in the effects of bezafibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes. Biochem Pharmacol (1989) 0.83
Effect on the expression of c-met, c-myc and PPAR-alpha in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator WY-14,643. Carcinogenesis (1996) 0.83
Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously. Cancer Res (1991) 0.82
The effect of aging on rat liver regeneration. Experientia (1982) 0.82
Aging decreases retinoic acid and triiodothyronine nuclear expression in rat liver: exogenous retinol and retinoic acid differentially modulate this decreased expression. Mech Ageing Dev (1997) 0.82
Aging-related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate-treated mice. A biochemical study and mechanistic approach. Mech Ageing Dev (1996) 0.81
The impact of aging on enzyme proteins of rat liver peroxisomes: quantitative analysis by immunoblotting and immunoelectron microscopy. Virchows Arch B Cell Pathol Incl Mol Pathol (1993) 0.81
Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis (1995) 0.81
A new cellular function for peroxisomes related to oxygen free radicals? Experientia (1990) 0.81
Peroxisome biogenesis disorders: identification of a new complementation group distinct from peroxisome-deficient CHO mutants and not complemented by human PEX 13. Biochem Biophys Res Commun (1998) 0.81
Cellular theories of aging as related to the liver. Hepatology (1985) 0.80
Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. Carcinogenesis (1996) 0.80
Rhizomelic chondrodysplasia punctata: biochemical studies of peroxisomes isolated from cultured skin fibroblasts. Arch Biochem Biophys (1991) 0.80
Effect of age and sex on allyl alcohol hepatotoxicity in rats: role of liver alcohol and aldehyde dehydrogenase activities. J Pharmacol Exp Ther (1987) 0.80
Time course of peroxisome biogenesis during adaptation to mild hyperthyroidism in rat liver: a morphometric/stereologic study by electron microscopy. Lab Invest (1982) 0.80
Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific MAbs. Hybridoma (1998) 0.80
Hyperinsulinemia inhibits hepatic peroxisomal beta-oxidation in rats. Horm Metab Res (1995) 0.79
Ion effects on macromolecules in aqueous solution. Nature (1976) 0.79
Evidence against peroxisome proliferation-induced hepatic oxidative damage. Biochem Pharmacol (1997) 0.79
Age-related changes in liver drug metabolism: structure vs function. Proc Soc Exp Biol Med (1980) 0.79
Fatty acids in control of gene expression. Nutr Rev (1998) 0.78
Fatty acids bind directly to and activate peroxisome proliferator-activated receptors alpha and gamma. Nutr Rev (1998) 0.78
Conclusive evidence that very-long-chain fatty acids are oxidized exclusively in peroxisomes in human skin fibroblasts. Biochem Biophys Res Commun (1991) 0.78
Role of oxidative stress in age dependent hepatocarcinogenesis by the peroxisome proliferator nafenopin in the rat. Cancer Res (1991) 0.76
Comparison of the inducing effect of dehydroepiandrosterone on hepatic peroxisome proliferation-associated enzymes in several rodent species. A short-term administration study. Biochem Pharmacol (1992) 0.76
Altered hepatic drug metabolism in senescent mice. Exp Gerontol (1980) 0.76
Age-related changes in the susceptibility to clofibric acid, a hypolipidemic agent, of male rat liver. Toxicol Lett (1995) 0.76
Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. Arch Dis Child Fetal Neonatal Ed (2008) 1.53
Central administration of perfluorooctanoic acid inhibits cutaneous inflammation. Inflamm Res (2005) 0.96
Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease. Crit Rev Toxicol (1998) 0.88
Correlation between thyroid hormone status and hepatic hyperplasia and hypertrophy caused by the peroxisome proliferator-activated receptor alpha agonist Wy-14,643. J Carcinog (2004) 0.82
Diminished energy metabolism and enhanced apoptosis in livers of B6C3F1 mice treated with the antihepatocarcinogen rotenone. Mol Cell Biochem (1999) 0.81
Carbohydrate and oxygen metabolism during hepatocellular proliferation: a study in perfused livers from mirex-treated rats. Hepatology (1991) 0.80
Regulation of perfluorooctanoic acid--induced peroxisomal enzyme activities and hepatocellular growth by adrenal hormones. Hepatology (1992) 0.79
Hyperinsulinemia inhibits hepatic peroxisomal beta-oxidation in rats. Horm Metab Res (1995) 0.79
Kinetics of aluminum in rats. III: Effect of route of administration. J Pharm Sci (1992) 0.79
Activated Kupffer cells attenuate the liver response to the peroxisome proliferator perfluorooctanoic acid. Mol Cell Biochem (1997) 0.78
Mechanism of aluminum-induced inhibition of hepatic glycolysis: inactivation of phosphofructokinase. J Pharmacol Exp Ther (1990) 0.78
Protection of liver by calcium entry blockers. Ann N Y Acad Sci (1988) 0.77
Enoximone inhibits hepatic mitochondrial long-chain acyl-CoA synthetase. Toxicol Lett (1994) 0.77
Selective inhibition of hepatic peroxisomal fatty acid beta-oxidation by enoximone. Life Sci (1992) 0.76
Jaw problems: Update on ARONJ. Br Dent J (2015) 0.75
Stimulation of myocyte insulin-responsive glucose transporters by the inhibition of fatty acid oxidation. Diabetes Res (1993) 0.75
Antagonism between salicylic acid and glucose in Saccharomyces cerevisiae. Toxicol Appl Pharmacol (1981) 0.75
Urinary bilharziasis in upper Egypt. I. A clinicopathological study. East Afr Med J (1972) 0.75
Ovarian adrenergic nerves directly participate in the control of luteinizing hormone-releasing hormone and beta-adrenergic receptors during puberty: a biochemical and autoradiographic study. Endocrinology (1987) 0.75
Proceedings: Effect of acetyl salicylic acid on platelet function in vivo. Thromb Diath Haemorrh (1975) 0.75
Urinary bilharziasis in upper Egypt. II. A bacteriological study. East Afr Med J (1972) 0.75
The ureterocalyceal system in normal pregnancy. A study using isotope renography and intravenous pyelography. Acta Obstet Gynecol Scand (1973) 0.75
Stimulation of fatty acid oxidation in myocytes by phosphodiesterase inhibitors and adenosine analogues. Life Sci (1991) 0.75
[Post-bilharzic bladder neck obstruction]. J Urol Nephrol (Paris) (1977) 0.75
Reduced induction of carbohydrate utilization by inhibition of fatty acid oxidation in myocytes from diabetic animals. Horm Metab Res (1995) 0.75
The lengthy type of post-bilharzial ureteral stricture. J Urol (1982) 0.75
The inhibition of long-chain fatty acyl-CoA synthetase by enoximone in rat heart mitochondria. J Cardiovasc Pharmacol (1992) 0.75
[Digitalis intoxication during the neonatal period: role of dehydration]. Arch Pediatr (2000) 0.75
Evaluation of hepatic metabolism of salicylic acid in perfused rat liver. J Pharm Sci (1994) 0.75
Management of bilharzial strictures of the lower ureter. Urol Int (1982) 0.75
Menadione causes selective toxicity to periportal regions of the liver lobule. Toxicol Lett (1987) 0.75
Stimulation of polyunsaturated fatty acid oxidation in myocytes by regulating its cellular uptake. On the rate limiting step of polyunsaturated fatty acid oxidation in heart. Life Sci (1991) 0.75
[Revelation of an acute lymphoblastic leukemia in the delivery room]. Arch Pediatr (2007) 0.75
Partial flap ureteroneocystostomy for bilharzial strictures of lower ureter. Urology (1982) 0.75